<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Primary angiitis of the central nervous system in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Primary angiitis of the central nervous system in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Primary angiitis of the central nervous system in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rula A Hajj-Ali, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Leonard H Calabrese, DO</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gene G Hunder, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott E Kasner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Philip Seo, MD, MHS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 17, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Central nervous system (CNS) vasculitis refers to a broad spectrum of diseases that result in inflammation and destruction of the blood vessels of the brain, spinal cord, and meninges. Angiitis, a synonym for vasculitis, refers generally to blood vessels on both the arterial and venous sides of the circulation.</p><p>Primary angiitis of the CNS (PACNS) is the preferred name for vasculitis that is confined to the CNS. CNS vasculitis is considered secondary when it occurs in the context of a systemic inflammatory disease, such as a systemic vasculitis or systemic lupus erythematosus (SLE), or an infectious process such as varicella zoster virus.</p><p>PACNS predominantly affects small- and medium-sized arteries of the brain parenchyma, spinal cord, and leptomeninges, resulting in symptoms and signs of CNS dysfunction. It is defined by inflammation of the cerebral vasculature without angiitis in other organs.</p><p>The protean manifestations of PACNS, along with the nonspecificity of available investigational modalities, pose a challenge for accurate diagnosis. Clinicians caring for patients with suspected PACNS should be familiar with its mimics to avoid misdiagnosis. PACNS can be mimicked closely in both its clinical presentation and radiologic manifestations by a number of other disorders. The most frequent mimic of PACNS is a group of disorders known collectively as the reversible cerebral vasoconstriction syndromes (RCVS). (See  <a class="medical medical_review" href="/z/d/html/14075.html" rel="external">"Reversible cerebral vasoconstriction syndrome"</a>.)</p><p>The clinical characteristics, diagnosis, and treatment of PACNS will be reviewed here. PACNS in children is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6401.html" rel="external">"Vasculitis in children: Incidence and classification", section on 'Primary angiitis of the central nervous system'</a>.)</p><p class="headingAnchor" id="H476042046"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Primary angiitis of the central nervous system (PACNS) is a rare disease. A retrospective analysis of 101 patients with PACNS reported an annual incidence rate of 2.4 cases per 1,000,000 person-years [<a href="#rid1">1</a>]. There is a 2:1 male predominance among reported cases [<a href="#rid2">2</a>]. The median age at diagnosis is 50 years, although it can occur at almost every age [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/6401.html" rel="external">"Vasculitis in children: Incidence and classification", section on 'Primary angiitis of the central nervous system'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">ETIOPATHOGENESIS</span><span class="headingEndMark"> — </span>The cause of primary angiitis of the central nervous system (PACNS) is unknown. Several potential etiologic agents or mechanisms have been proposed, but understanding of the cause of PACNS remains highly speculative. Various infectious agents have been proposed as etiologic factors, such as varicella zoster virus, West Nile virus, <em>Mycoplasma gallisepticum</em>, and human immunodeficiency virus (HIV) [<a href="#rid3">3-11</a>].</p><p>Cerebral amyloid angiopathy and PACNS have been described together in some patients, and associations between amyloid deposition have also been proposed as a trigger [<a href="#rid12">12-18</a>]. (See  <a class="medical medical_review" href="/z/d/html/1128.html" rel="external">"Cerebral amyloid angiopathy", section on 'Clinical and diagnostic features'</a>.)</p><p>Although the cause of PACNS is unknown, inflammation of the CNS causes the vessels to become narrowed, occluded, and thrombosed, resulting in tissue ischemia and necrosis of the territories of the involved vessels. PACNS is more likely to affect blood vessels in the cerebral cortex and leptomeninges than subcortical regions. Blood vessels supplying cranial nerves may also be involved.</p><p class="headingAnchor" id="H7"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>Primary angiitis of the central nervous system (PACNS) is characterized by a long prodromal period, with few patients presenting acutely [<a href="#rid19">19,20</a>]. The vasculitis can affect any part of the CNS, causing the clinical manifestations to be highly variable and nonspecific [<a href="#rid2">2,21-23</a>].</p><p>Headache is the most commonly reported symptom, occurring in about 60 percent of patients [<a href="#rid1">1,2</a>]. The headache typically varies in description, but is usually subacute and insidious, in contrast to the sudden-onset thunderclap headache that is observed with reversible cerebral vasoconstriction syndromes (RCVS). Other symptoms include cognitive impairment, stroke, and transient ischemic attack, which are present in 30 to 50 percent of patients [<a href="#rid1">1,2,19</a>]. Patients with PACNS who develop strokes usually present with more than a single stroke in different anatomic territories.</p><p>Other less common symptoms, including cranial neuropathies, ataxia, seizure, and coma, have been reported. Signs and symptoms suggestive of systemic vasculitis, such as peripheral neuropathy, fever, weight loss, or rash, are usually lacking.</p><p>Spinal cord involvement occurs alone or coincides with parenchymal brain involvement [<a href="#rid24">24</a>]. Angiitis affecting the spinal cord usually presents as a myelopathy, with pain, motor weakness, and sensory findings. (See  <a class="medical medical_review" href="/z/d/html/5093.html" rel="external">"Disorders affecting the spinal cord", section on 'Spinal cord infarction'</a>.)</p><p>Symptoms and signs of untreated PACNS progress over the course of months. In one series, the mean time from symptom onset to diagnosis was 170 days [<a href="#rid2">2</a>]. However, if left untreated, PACNS will progress; thus the diagnosis of PACNS will be less likely in patients presenting with stable symptoms and signs for many months without progression of any radiographic findings. This is an important contrast to the RCVS, which typically have a more acute onset and much shorter time to diagnosis. (See <a class="local">'Alternative diagnoses'</a> below and  <a class="medical medical_review" href="/z/d/html/14075.html" rel="external">"Reversible cerebral vasoconstriction syndrome"</a>.)</p><p class="headingAnchor" id="H8"><span class="h1">DIAGNOSTIC APPROACH</span><span class="headingEndMark"> — </span>The diagnosis of primary angiitis of the central nervous system (PACNS) is challenging as the symptoms are generally nonspecific and there is no specific diagnostic test. The workup for patients who may have PACNS must proceed simultaneously with the systematic evaluation and exclusion of other disorders. (See <a class="local">'Alternative diagnoses'</a> below.)</p><p class="headingAnchor" id="H854837667"><span class="h2">When to suspect the diagnosis</span><span class="headingEndMark"> — </span>While there is no characteristic presentation of PACNS, there are some scenarios that are highly suspicious. PACNS should be suspected when strokes, more often recurrent, occur in young patients with no identifiable cardiovascular or hypercoagulable risk factors; in the development of cognitive dysfunction with or without headaches; and in recurrent or persistent focal neurologic symptoms, abnormal cerebrovascular imaging obtained in the setting of an unexplained neurological deficit, or unexplained spinal cord dysfunction not associated with systemic disease or any other process.</p><p class="headingAnchor" id="H854836086"><span class="h2">Alternative diagnoses</span><span class="headingEndMark"> — </span>The clinician must remember that when PACNS is suspected, the correct diagnosis is usually something else. As a result, careful exclusion of other disorders is essential. Because of the importance of eliminating a lengthy list of alternative diagnoses, the differential diagnosis of PACNS is discussed in detail below before making the diagnosis.</p><p>The major categories of disease in the differential diagnosis of PACNS are presented below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Infection</strong> – When considering a diagnosis of PACNS, it is most important to rule out infection since unwarranted immunosuppression can have devastating consequences. A number of bacterial, mycobacterial, viral, fungal, and rickettsial infections can mimic PACNS. Prompt culture of all potential sites of infection, including the cerebrospinal fluid (CSF), is therefore essential. The detection of pathogens associated with CNS vasculitis, especially in the setting of a chronic meningitis, may be enhanced via the use of a variety of serologies and targeted molecular studies (ie, polymerase chain reaction [PCR]). The application of next-generation sequencing has demonstrated some utility in detecting novel pathogens not clinically suspected and obviating the need for brain biopsy, but its place in the diagnostic algorithm remains to be established [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">Organisms that cause subacute or chronic infections are the ones most likely to imitate PACNS. The major organisms of concern are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>Treponema pallidum.</em> (See  <a class="medical medical_review" href="/z/d/html/7599.html" rel="external">"Neurosyphilis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>Borrelia burgdorferi.</em> (See  <a class="medical medical_review" href="/z/d/html/7913.html" rel="external">"Clinical manifestations of Lyme disease in adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>Bartonella</em> species. (See  <a class="medical medical_review" href="/z/d/html/5512.html" rel="external">"Bartonella infections in people with HIV", section on 'Bacillary angiomatosis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>Mycobacterium tuberculosis.</em> (See  <a class="medical medical_review" href="/z/d/html/8009.html" rel="external">"Central nervous system tuberculosis: An overview"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Herpesviruses such as varicella zoster virus and cytomegalovirus. Varicella zoster has been associated with a wide range of vascular disease ranging from granulomatous involvement of the aorta, to a syndrome resembling giant cell arteritis, granulomatous angiitis of the central nervous system, and stroke, and thus should be carefully searched for in virtually all settings [<a href="#rid26">26</a>] (see  <a class="medical medical_review" href="/z/d/html/8271.html" rel="external">"Varicella zoster virus vasculopathy"</a>). The clinical implications of identifying positive serology for varicella zoster virus in the absence of detectable virus remains controversial [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hepatitis B and C viruses, which can be associated with polyarteritis nodosa and mixed cryoglobulinemia, respectively. (See  <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">"Clinical manifestations and diagnosis of polyarteritis nodosa in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">"Overview of cryoglobulins and cryoglobulinemia"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HIV infection. (See  <a class="medical medical_review" href="/z/d/html/3718.html" rel="external">"Approach to the patient with HIV and central nervous system lesions"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fungi such as <em>Aspergillus</em>, <em>Coccidioides</em>, and <em>Histoplasma</em> species. (See  <a class="medical medical_review" href="/z/d/html/1297.html" rel="external">"Pathogenesis, clinical manifestations, and diagnosis of brain abscess"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cysticercosis can involve middle-size cerebral vessels of the subarachnoid space, often without clinical evidence of cerebral ischemia [<a href="#rid28">28</a>]. Cysticercosis is endemic in many regions of Central and South America, sub-Saharan Africa, India, and Asia. (See  <a class="medical medical_review" href="/z/d/html/5678.html" rel="external">"Cysticercosis: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reversible cerebral vasoconstriction syndromes</strong> – The RCVS are a group of disorders linked by prolonged but reversible vasoconstriction of the cerebral arteries [<a href="#rid29">29</a>]. The RCVS are typically associated with severe, acute-onset headaches that can recur intermittently for days to weeks, sometimes accompanied by neurologic symptoms and signs. The headaches associated with the RCVS are usually "thunderclap" in nature. Ischemic and/or hemorrhagic stroke may occur in the setting of RCVS. Thus, despite the reversibility of vasoconstriction, these disorders are not always characterized by benign prognoses. (See  <a class="medical medical_review" href="/z/d/html/14075.html" rel="external">"Reversible cerebral vasoconstriction syndrome"</a>.)</p><p></p><p class="bulletIndent1">While there are some signs and symptoms common to both conditions, including headache, focal deficits, stroke, seizures, and angiographic irregularities, the nature of the headaches and imaging abnormalities are quite different and discussed separately. (See  <a class="medical medical_review" href="/z/d/html/14075.html" rel="external">"Reversible cerebral vasoconstriction syndrome", section on 'Angiographic differential'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Systemic vasculitis involving the brain</strong> – Some forms of vasculitis can involve the CNS. The ones most likely to do so are the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Behçet syndrome (see  <a class="medical medical_review" href="/z/d/html/8223.html" rel="external">"Clinical manifestations and diagnosis of Behçet syndrome", section on 'Neurologic disease'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Polyarteritis nodosa (see  <a class="medical medical_review" href="/z/d/html/8245.html" rel="external">"Clinical manifestations and diagnosis of polyarteritis nodosa in adults", section on 'Neurologic disease'</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vasculitides associated with antineutrophil cytoplasmic antibodies, including granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (see  <a class="medical medical_review" href="/z/d/html/3117.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/4363.html" rel="external">"Epidemiology, pathogenesis, and pathology of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)"</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cryoglobulinemic vasculitis (see  <a class="medical medical_review" href="/z/d/html/1825.html" rel="external">"Overview of cryoglobulins and cryoglobulinemia"</a>)</p><p></p><p class="bulletIndent1">The diagnosis of CNS vasculitis secondary to a systemic form of vasculitis is usually inferred from biopsy or angiography of a non-CNS site. In most such patients, the systemic vasculitis is an established diagnosis before the CNS is involved. We assign high importance to performing a thorough evaluation to exclude an infectious etiology of the CNS process, given the immunosuppressive treatments that patients are usually receiving for their systemic vasculitis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other systemic rheumatic diseases </strong>– CNS manifestations due to other systemic rheumatic diseases may reflect vasculitis or other mechanisms and can occur with or without systemic symptoms. In this setting, diagnosis of the underlying diseases is frequently based upon vasculitic or non-vasculitic clinical features in organs outside the CNS, combined with selected laboratory results. The systemic rheumatic diseases most likely to involve the CNS and create confusion with the diagnosis of PACNS are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Systemic lupus erythematosus and related conditions – Systemic lupus erythematosus (SLE), Sjögren's disease, mixed connective tissue disease, and dermatomyositis can all be associated with CNS involvement. (See  <a class="medical medical_review" href="/z/d/html/4863.html" rel="external">"Neurologic and neuropsychiatric manifestations of systemic lupus erythematosus"</a> and  <a class="medical medical_review" href="/z/d/html/5593.html" rel="external">"Clinical manifestations of Sjögren’s disease: Extraglandular disease"</a> and  <a class="medical medical_review" href="/z/d/html/7546.html" rel="external">"Mixed connective tissue disease"</a> and  <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">"Clinical manifestations of dermatomyositis and polymyositis in adults"</a>.)</p><p></p><p class="bulletIndent2">Neuropathologic abnormalities in lupus include multifocal microinfarcts, cortical atrophy, gross infarcts, hemorrhage, ischemic demyelination, and patchy, multiple sclerosis-like demyelination. The most common microscopic brain finding in SLE is microvasculopathy, described as "healed vasculitis" consistent with hyalinization, thickening, and thrombus formation [<a href="#rid30">30-32</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nonvasculitic autoimmune inflammatory meningoencephalitis – Nonvasculitic autoimmune inflammatory meningoencephalitis (NAIM) is a syndrome characterized clinically by dementia that occurs in some patients with this disorder at a younger age of onset, rapid progression with significant cognitive and behavioral features, absence of family history, abnormal electroencephalography (EEG) findings, and elevated levels of inflammatory markers [<a href="#rid33">33</a>]. The CNS involvement that may be seen in Hashimoto thyroiditis is considered as a form of NAIM. The pathologic findings of NAIM are those of a panencephalitis without evidence of a vasculitis [<a href="#rid33">33</a>]. Patients with NAIM are usually successfully treated with glucocorticoids. (See  <a class="medical medical_review" href="/z/d/html/4821.html" rel="external">"Hashimoto encephalopathy", section on 'Nonvasculitic autoimmune inflammatory meningoencephalitis'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Rheumatoid arthritis – Rheumatoid vasculitis occasionally involves the CNS. However, the most common neurologic manifestation of rheumatoid vasculitis is vasculitic neuropathy. (See  <a class="medical medical_review" href="/z/d/html/8237.html" rel="external">"Clinical manifestations and diagnosis of rheumatoid vasculitis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Antiphospholipid syndrome – The antiphospholipid syndrome can cause CNS dysfunction due to strokes caused by intracerebral clotting events, emboli associated with verrucous endocarditis, and white matter lesions suggestive of a vasculopathy. (See  <a class="medical medical_review" href="/z/d/html/4667.html" rel="external">"Clinical manifestations of antiphospholipid syndrome"</a>.)</p><p></p><p class="bulletIndent1">Many but not all cases of the Sneddon syndrome, the combination of livedo reticularis and cerebrovascular lesions, are associated with antiphospholipid antibodies. However, the Sneddon syndrome is unlikely to be confused with PACNS if the livedo reticularis is appreciated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atherosclerosis</strong> – Atherosclerosis of intracranial vessels can mimic the angiographic findings of PACNS [<a href="#rid2">2,34</a>]. The patient with multiple atherosclerotic risk factors and CNS dysfunction such as evidence of a cerebrovascular accident is much more likely to have atherosclerosis than PACNS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cerebral emboli </strong>– Cerebral emboli can result in multifocal vascular occlusions that suggest the diagnosis of vasculitis. As many as 30 to 40 percent of ischemic strokes remain cryptogenic despite the availability of transesophageal echocardiography, carotid ultrasonography, and magnetic resonance angiography (MRA) to help identify embolic sources. (See  <a class="medical medical_review" href="/z/d/html/1090.html" rel="external">"Cryptogenic stroke and embolic stroke of undetermined source (ESUS)"</a> and  <a class="medical medical_review" href="/z/d/html/1083.html" rel="external">"Overview of the evaluation of stroke", section on 'Embolic stroke'</a>.)</p><p></p><p class="bulletIndent1">Various types of embolic events can create confusion with PACNS. These include paradoxical emboli in patients with patent foramen ovale as well as emboli in patients with atrial fibrillation, atrial myxoma, and nonbacterial thrombotic endocarditis. (See  <a class="medical medical_review" href="/z/d/html/91781.html" rel="external">"Nonbacterial thrombotic endocarditis"</a> and  <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation", section on 'Prevention of thromboembolism'</a> and  <a class="medical medical_review" href="/z/d/html/1420.html" rel="external">"Patent foramen ovale", section on 'Cryptogenic stroke'</a>.)</p><p></p><p class="bulletIndent1">Atheroemboli are another cause of embolic stroke that may be confused with PACNS. Atheroemboli are often released from vessels other than the carotid arteries (especially the aorta), with a predilection for the middle cerebral artery [<a href="#rid35">35</a>]. Systemic signs of atheroembolism (eg, livedo reticularis, acute renal failure), if present, would exclude PACNS. (See  <a class="medical medical_review" href="/z/d/html/8184.html" rel="external">"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravascular lymphoma</strong> – Intravascular lymphoma that leads to widespread occlusion of small vessels is an occasional mimicker of PACNS [<a href="#rid36">36-38</a>]. Appropriate immunohistochemistry staining as well as B- and T-cell markers should be performed on biopsy specimens even with the pathologic finding of angiitis, since the presence of vasculitic changes does not exclude an underlying lymphoproliferative condition. Lymph node, bone marrow, and CSF involvement may not be evident at presentation, as delays of up to five years have been reported before the emergence of extracranial disease [<a href="#rid3">3</a>]. (See  <a class="medical medical_review" href="/z/d/html/4738.html" rel="external">"Intravascular large B cell lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Miscellaneous</strong> – A number of other diseases that can mimic PACNS include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cerebral artery dissection – Cervical internal carotid artery dissection occasionally presents with headache and scintillating scotomata in the ipsilateral visual field. Many patients with carotid or vertebral artery dissections progress to cerebral ischemia. The combination of headache followed by stroke mimics PACNS. (See  <a class="medical medical_review" href="/z/d/html/3344.html" rel="external">"Migraine-associated stroke: risk factors, diagnosis, and prevention"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sarcoidosis – Approximately 5 percent of patients with sarcoidosis develop clinically evident neurological involvement. In a manner similar to PACNS, sarcoidosis can be associated with granulomatous brain masses, encephalopathy, and/or meningeal disease. (See  <a class="medical medical_review" href="/z/d/html/4834.html" rel="external">"Neurologic sarcoidosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Paraneoplastic and autoimmune encephalitis – These are inflammatory conditions of the brain with many etiologies. Some are related to cancer and others are associated with antibodies against neuronal cell surface and synaptic protein. (See  <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">"Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Susac syndrome – Susac syndrome is a rare, poorly characterized disorder associated with the clinical triad of visual loss caused by branch retinal artery occlusions, sensorineural hearing loss, and subacute encephalopathy [<a href="#rid39">39,40</a>]. The presence of hyperintense lesions in the corpus callosum on T2-weighted MR images may be a clue to the diagnosis [<a href="#rid41">41,42</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>CADASIL – CADASIL is the acronym for <strong>c</strong>erebral <strong>a</strong>utosomal <strong>d</strong>ominant <strong>a</strong>rteriopathy with <strong>s</strong>ubcortical <strong>i</strong>nfarcts and <strong>l</strong>eukoencephalopathy. This disorder is a heritable, noninflammatory vasculopathy resulting from mutations in the gene for the protein Notch 3.</p><p></p><p class="bulletIndent2">The simplest way of diagnosing CADASIL and distinguishing it from PACNS is via a skin biopsy of clinically normal skin. The demonstration of granular osmiophilic material within the vascular basal lamina of arteries, arterioles, and precapillaries is diagnostic of CADASIL. (See  <a class="medical medical_review" href="/z/d/html/1091.html" rel="external">"Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mitochondrial encephalomyopathy, lactic acidosis, and stroke syndrome (MELAS) is a mitochondrial genetic disorder caused by a point mutation at nucleotide 3243 (A3243G), leading to stroke-like episodes before age 40, seizures, dementia, and ragged-red fibers in muscle [<a href="#rid43">43</a>]. (See  <a class="medical medical_review" href="/z/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis", section on 'MELAS'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cerebroretinal vasculopathy syndrome is an autosomal dominant retinal vasculopathy with cerebral leukodystrophy, leading to stroke and dementias with middle-age onset [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Moyamoya disease – Moyamoya disease is a cerebrovascular disease of unknown cause characterized by progressive stenosis of the intracranial internal carotid arteries and their proximal branches. It generally affects adults in the third to fourth decade of life, and in adults it can cause strokes, recurrent transient ischemic attacks, sensorimotor paralysis, seizures, and/or migraine-like headaches. (See  <a class="medical medical_review" href="/z/d/html/1131.html" rel="external">"Moyamoya disease and moyamoya syndrome: Etiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other conditions include amyloid angiopathy and inflammatory bowel disease-associated cerebral vasculitis. (See  <a class="medical medical_review" href="/z/d/html/1128.html" rel="external">"Cerebral amyloid angiopathy"</a>.)</p><p></p><p class="headingAnchor" id="H1123088451"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>As part of the diagnostic evaluation, all patients should undergo routine laboratory testing and serological evaluations to rule out systemic disease, whether infectious or inflammatory. Obtaining cerebrospinal fluid is an essential step in the evaluation and should only be omitted if there are contraindications to perform a lumbar puncture. The evaluation also includes cerebrovascular imaging and/or obtaining tissue biopsy of the leptomeninges and brain for either ruling out other etiologies or confirming suspected PACNS. Initial neuroimaging should include MR imaging (MRI), since a normal MRI is very unlikely in PACNS. The selection of additional neuroimaging studies depends upon the initial MRI findings and individual patient characteristics. The results of the various tests must be interpreted in conjunction with each other in order to determine whether to treat the patient with immunosuppressive therapy, even in the setting of a negative brain biopsy.</p><p class="headingAnchor" id="H9"><span class="h3">Laboratory testing to exclude alternative diagnoses</span><span class="headingEndMark"> — </span>The purpose of laboratory testing is primarily to exclude an underlying systemic disease or alternative diagnoses.</p><p>We perform the following basic laboratory tests in patients suspected of having PACNS:</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count with differential</p><p class="bulletIndent1"><span class="glyph">●</span>Serum urea nitrogen and creatinine</p><p class="bulletIndent1"><span class="glyph">●</span>Serum aspartate and alanine aminotransferases</p><p class="bulletIndent1"><span class="glyph">●</span>Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)</p><p class="bulletIndent1"><span class="glyph">●</span>Urinalysis</p><p></p><p>Acute phase reactants such as the ESR and CRP are usually normal in PACNS. An elevated ESR and CRP should raise suspicion of systemic involvement by either an infectious or inflammatory process.</p><p>We also perform the following serologic assays to exclude other underlying systemic rheumatic diseases:</p><p class="bulletIndent1"><span class="glyph">●</span>Antinuclear antibodies (ANA)</p><p class="bulletIndent1"><span class="glyph">●</span>Antibodies to the Ro/SSA, La/SSB, Sm, and RNP antigens</p><p class="bulletIndent1"><span class="glyph">●</span>Antibodies to double-stranded deoxyribonucleic acid (DNA)</p><p class="bulletIndent1"><span class="glyph">●</span>Antiphospholipid antibodies (lupus anticoagulant [LA], IgG, and IgM anticardiolipin [aCL] antibodies; and IgG and IgM anti-beta2-glycoprotein [GP] I)</p><p class="bulletIndent1"><span class="glyph">●</span>Antineutrophil cytoplasmic antibodies (ANCA)</p><p class="bulletIndent1"><span class="glyph">●</span>Serum C3 and C4</p><p class="bulletIndent1"><span class="glyph">●</span>Serum cryoglobulins</p><p class="bulletIndent1"><span class="glyph">●</span>Serum and urine protein electrophoresis with immune electrophoresis</p><p class="bulletIndent1"><span class="glyph">●</span>Quantitative immunoglobulin levels (IgG, IgM, IgA)</p><p></p><p>Testing for infections appropriate to the clinical circumstances is critical, as the treatment for infectious causes of CNS dysfunction differs radically from the therapy for immune-mediated disorders. A thorough history for any risk factors for immunodeficiency as well as travel history is important in the assessment for any exposure or an immunodeficiency state. In addition to cultures of the blood, CSF, and other body fluids, diagnostic tests for infection may include assays for the following organisms:</p><p class="bulletIndent1"><span class="glyph">●</span><em>Treponema pallidum</em></p><p class="bulletIndent1"><span class="glyph">●</span><em>Borrelia burgdorferi</em></p><p class="bulletIndent1"><span class="glyph">●</span>Bartonella species</p><p class="bulletIndent1"><span class="glyph">●</span><em>Mycobacterium tuberculosis</em></p><p class="bulletIndent1"><span class="glyph">●</span>Herpesviruses (varicella zoster virus, cytomegalovirus, others)</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatitis B and C viruses</p><p class="bulletIndent1"><span class="glyph">●</span>HIV</p><p class="bulletIndent1"><span class="glyph">●</span>Cysticercosis</p><p></p><p class="headingAnchor" id="H11"><span class="h3">Lumbar puncture</span><span class="headingEndMark"> — </span>Analysis of the CSF is a crucial part of the evaluation of patients with potential PACNS and should be performed in all patients unless there are contraindications. The importance of CSF analysis in excluding any infectious or malignant process and the performance of adequate stains and cultures of the CSF cannot be overemphasized. (See  <a class="medical medical_review" href="/z/d/html/1278.html" rel="external">"Molecular diagnosis of central nervous system infections"</a> and  <a class="medical medical_review" href="/z/d/html/4832.html" rel="external">"Lumbar puncture: Technique, contraindications, and complications in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1285.html" rel="external">"Cerebrospinal fluid: Physiology and utility of an examination in disease states"</a>.)</p><p>The CSF is abnormal in 80 to 90 percent of patients with pathologically documented disease. Normal CSF findings can occur with localized disease and in patients presenting with mass-like lesions. There are no specific abnormalities of the CSF in PACNS; however, the CSF findings in the majority of patients show an aseptic meningitis pattern with modest lymphocytic pleocytosis, normal glucose levels, elevated protein level, and occasionally the presence of oligoclonal bands and elevated IgG synthesis [<a href="#rid19">19</a>]. By contrast, in the RCVS, the most common mimic of PACNS, the CSF analysis is usually normal or reflects findings of subarachnoid hemorrhage if this is present [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H12"><span class="h3">Neuroimaging</span><span class="headingEndMark"> — </span>Various neuroimaging modalities can be used to assess for both parenchymal and vascular abnormalities in the evaluation of possible PACNS. MRI should be performed in all patients with PACNS. The selection of additional neuroimaging modalities depends on the initial MRI findings and individual patient characteristics. Some clinicians may choose to order an MRA at the same time as the initial MRI out of convenience because the patient is in the scanner, though it lacks both sensitivity and specificity for PACNS. Computed tomography angiography (CTA) may be more sensitive for detecting vascular irregularities than MRA, but is far less sensitive than catheter-based angiography. (See <a class="local">'MRI'</a> below and <a class="local">'MR angiography and CT angiography'</a> below.)</p><p>Conventional angiography remains an important part of the diagnostic testing for suspected PACNS, and our authors obtain angiography in patients who have MRI findings of multiple cortical and subcortical infarcts that are otherwise unexplained. Angiography can detect segmental narrowing in multiple vessels that are typical of, though not pathognomonic for, PACNS, and help further rule out alternative diagnoses such as atherosclerosis, moyamoya, and dissection. These tests may also be helpful in selecting a location for brain biopsy if needed. (See <a class="local">'Conventional angiography'</a> below.)</p><p class="headingAnchor" id="H271565853"><span class="h4">MRI</span><span class="headingEndMark"> — </span>MRI is sensitive in detecting abnormalities in PACNS and should be performed in all patients suspected to have PACNS. MRI of the brain commonly shows multiple infarcts in multiple vascular territories, and often in areas of the brain not affected by more common causes of stroke (such as the corpus callosum). However, these findings are not specific for PACNS and the interpretation of MRI findings should be performed by an expert neuroradiologist who is familiar with the findings of CNS vasculitis and its radiologic mimics. In addition, there may rarely be tumor-like lesions [<a href="#rid46">46-48</a>]. Conversely, a negative MRI carries a high negative predictive value for the diagnosis of PACNS [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H271566089"><span class="h4">MR angiography and CT angiography</span><span class="headingEndMark"> — </span>In most cases of PACNS, the medium and small intracranial arteries are affected rather than the large proximal arteries. MRA and CTA are most reliable for the assessment of the large proximal arteries and therefore are inadequate for the demonstration of more distal vasculopathy. Notably, the finding of narrowing of multiple large proximal intracranial arteries as detected by MRA or CTA should suggest an alternative diagnosis, such as atherosclerosis, dissection, moyamoya disease, or reversible cerebral vasoconstriction in the appropriate clinical setting. The resolution of conventional angiogram remains superior to MRA and CTA in detecting abnormalities in smaller vessels.</p><p class="headingAnchor" id="H13"><span class="h4">Conventional angiography</span><span class="headingEndMark"> — </span>Visualization of the cerebral vasculature with conventional angiography is a common part of the investigation when PACNS is suspected based on the clinical presentation and MRI findings described above. (See <a class="local">'MRI'</a> above and  <a class="medical medical_review" href="/z/d/html/1085.html" rel="external">"Neuroimaging of acute stroke", section on 'Digital subtraction angiography'</a>.)</p><p>Classic cerebral angiography studies in PACNS reveal findings of segmental narrowing referred to as "beading," usually in the medium and small arteries. Involvement of several sites of the cerebral circulation is typical of PACNS  (<a class="graphic graphic_picture graphicRef52006" href="/z/d/graphic/52006.html" rel="external">picture 1</a>). Other findings include circumferential or eccentric vessel irregularities. While the findings are characteristic of cerebral arteritis, these findings are not specific, and may be encountered in non-vasculitic disorders such as atherosclerosis and vasospasm [<a href="#rid43">43</a>]. PACNS has a host of potential mimickers of its angiographic features (see <a class="local">'Alternative diagnoses'</a> above). In addition, angiographic findings interpreted as "consistent with vasculitis" greatly outnumber true cases of PACNS. Thus, a positive angiogram does not make the diagnosis of PACNS. In a study of 38 patients with suspected PACNS, 14 patients had typical angiographic findings of vasculitis [<a href="#rid49">49</a>]. None were found to have vasculitic changes at brain biopsy. This study reflects the poor specificity of the angiographic findings and/or the limited sensitivity of brain biopsy.</p><p>The sensitivity of angiography is also limited, and in two series of patients PACNS, the sensitivity of angiography in biopsy-proven PACNS cases was only 60 percent [<a href="#rid50">50,51</a>]. PACNS may be limited to the small vessels that are below the resolution of conventional angiography, which is particularly common when the pattern of infarction is predominantly subcortical, and thus a negative angiogram cannot be used to exclude the diagnosis of PACNS.</p><p>In unusual cases of PACNS, the disease presents radiologically as a CNS mass lesion, manifested on angiography by the presence of an avascular mass effect.</p><p>Proper interpretation of CNS angiograms requires insight into the clinical context of the specific patient, experience in reading abnormal angiograms, and thorough appreciation of the range of normal findings within the circulation of the internal carotid artery and its intracerebral branches  (<a class="graphic graphic_diagnosticimage graphicRef63788" href="/z/d/graphic/63788.html" rel="external">image 1</a>).</p><p>Although it is not common to perform serial angiograms as a way of following response to treatment, repeat angiography is sometimes useful if the diagnosis remains unclear days to weeks after the performance of an initial study. A rapid change in angiographic appearance (eg, evolution from a flagrantly abnormal study to one that is essentially normal within days or weeks) argues compellingly for an RCVS rather than PACNS  (<a class="graphic graphic_diagnosticimage graphicRef66139" href="/z/d/graphic/66139.html" rel="external">image 2</a>) [<a href="#rid29">29</a>]. (See  <a class="medical medical_review" href="/z/d/html/1085.html" rel="external">"Neuroimaging of acute stroke", section on 'Digital subtraction angiography'</a>.)</p><p class="headingAnchor" id="H17"><span class="h3">Brain and leptomeningeal biopsy</span></p><p class="headingAnchor" id="H22127408"><span class="h4">Selecting patients for brain biopsy</span><span class="headingEndMark"> — </span>The gold standard for the diagnosis of PACNS is histopathology. A brain biopsy should be performed in most patients with suspected PACNS. A biopsy will help histologically identify PACNS as well as exclude other lesions or vasculitis mimics, particularly infection or malignancy. Sampling of the leptomeninges as well as the underlying cortex increases the diagnostic yield; however, the test characteristics of the brain biopsy are far from optimal. The sensitivity of brain biopsy for PACNS is approximately 75 percent, thus leaving the clinician with a false negative rate of 25 percent [<a href="#rid50">50</a>]. A meta-analysis revealed a diagnostic yield of 74.7 percent (95% CI 64.0-84.1 percent) for suspected PACNS [<a href="#rid52">52</a>]. Biopsies may also identify a cause other than PACNS in up to 39 to 50 percent of patients [<a href="#rid53">53,54</a>]. In other words, a brain biopsy not only establishes a diagnosis in the setting of suspected PACNS in roughly 70 percent of cases but also may provide an alternative diagnosis in a fair number of patients [<a href="#rid55">55</a>].</p><p>There are two settings of particular concern where obtaining tissue is paramount:</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of a focal lesion on MR with characteristics that suggest an inflammatory or infectious process, but noninvasive approaches to diagnosis have failed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The presence of a mass lesion in the brain for which the principal concern is usually malignancy or abscess. PACNS is occasionally a surprise finding. In such cases, the finding of vasculitis on pathologic exam does not exclude the diagnosis of infection or malignancy, and appropriate stains and markers should be pursued for accurate diagnosis.</p><p></p><p>Biopsy of a radiologically abnormal area heightens the sensitivity of brain/leptomeningeal biopsies. In the absence of a focal lesion within the brain parenchyma, the temporal tip of the nondominant hemisphere is the preferred biopsy site [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H271565621"><span class="h4">Histopathology</span><span class="headingEndMark"> — </span>Histopathologic findings in the brain in patients with PACNS may include the presence of Langerhans or foreign body giant cells, necrotizing vasculitis, or lymphocytic vasculitis. PACNS is referred to as granulomatous angiitis of the CNS (GACNS) if the pathologic findings are those of granulomatous angiitis affecting the small and medium leptomeningeal and cortical arteries  (<a class="graphic graphic_diagnosticimage graphicRef101671" href="/z/d/graphic/101671.html" rel="external">image 3</a>) [<a href="#rid23">23,57</a>]. However, the classic finding of granulomatous segmental vasculitis with Langerhans or foreign body giant cells is present in less than 50 percent of the biopsies [<a href="#rid58">58</a>]. The biopsy is not granulomatous in most such cases, and only reveals lymphocytic vasculitis.</p><p>Appropriate stains, viral studies, and cultures should be performed on the biopsies, since the finding of vasculitis does not preclude the diagnosis of an associated infection or a lymphoproliferative process that is causing the vasculitis.</p><p>Because of the focal and segmental distribution of CNS vasculitis, a positive biopsy is diagnostic, but a single isolated negative biopsy does not exclude primary or secondary CNS vasculitis [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H27"><span class="h2">Establishing the diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of PACNS is based upon a constellation of symptoms and signs in the setting of supportive studies, and the exclusion of alternative diagnoses. (See <a class="local">'Alternative diagnoses'</a> above.)</p><p>The diagnosis of PACNS can usually be made when all of the following are present:</p><p class="bulletIndent1"><span class="glyph">●</span>An acquired, otherwise unexplained neurological deficit </p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of either classic angiographic or histopathologic features of angiitis within the CNS</p><p class="bulletIndent1"><span class="glyph">●</span>No evidence of systemic vasculitis or any other condition that could elicit the angiographic or pathologic findings</p><p></p><p>These clinical findings are consistent with the diagnostic criteria that were proposed in 1988 [<a href="#rid34">34</a>].</p><p>There are patients in whom the diagnosis of PACNS is made without meeting all the criteria described above. In such scenarios, the term "atypical/possible PACNS" has been used to describe the uncertainty about the diagnosis or the variation from the typical pathologic findings. This usually includes lymphocytic PACNS, angiographically defined PACNS, and a mass lesion presentation.</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphocytic PACNS – This group of patients is distinguished by lymphocytic infiltration rather than granulomatous findings on the pathologic examination. When the pathologic findings are predominantly lymphocytic, careful pathologic examination and immunophenotyping should be performed to rule out a lymphomatous CNS process.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Angiographically defined PACNS – This group is diagnosed by an abnormal cerebrovascular study and CSF examination, but with a normal CNS biopsy. The culprit vessel size involvement is usually medium-sized vessels rather than the small vessel typically seen in PACNS. In this subset, a diligent workup should be performed to rule out other vasculopathies, given the poor specificity of the cerebrovascular imaging study in the diagnosis of PACNS. Moreover, signs of inflammatory brain changes should be present, such as an abnormal CSF finding or enhancement of arterial vessel walls (in the absence of other causes of arterial enhancement). The RCVS, in particular, should be ruled out since this is a major mimic of this category.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mass lesion presentation – These patients present with a solitary cerebral mass lesion. The diagnosis is usually a surprise after pathologic findings of a vasculitic process are observed as part of the pathologic evaluation. A complete analysis of the biopsy is mandatory to exclude alternative diagnoses, especially infection and malignancy even with the finding of vasculitis.</p><p></p><p class="headingAnchor" id="H30"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Immunosuppressive therapy has been associated with success in central nervous system (CNS) vasculitis [<a href="#rid1">1</a>]. However, no prospective studies of any of the therapies described below have been conducted in patients with primary angiitis of the CNS (PACNS).</p><p>Thus, our suggestions for treatment are influenced by anecdotal evidence related to PACNS and extrapolation of therapeutic strategies from other forms of vasculitis and retrospectively assessed experience with PACNS [<a href="#rid1">1,21,22</a>]. The suggested approach for the treatment of PACNS is similar to the therapy of severe polyarteritis nodosa. (See  <a class="medical medical_review" href="/z/d/html/8244.html" rel="external">"Treatment and prognosis of polyarteritis nodosa", section on 'Treatment of severe PAN'</a>.)</p><p class="headingAnchor" id="H31"><span class="h2">Initial therapy of suspected PACNS</span><span class="headingEndMark"> — </span>If the initial clinical evaluation has excluded infection with a reasonable degree of confidence and PACNS remains a diagnostic possibility, empiric therapy with glucocorticoids may be appropriate while the full workup is completed.</p><p>There have been no controlled trials in selecting the route of glucocorticoids in the management of the acute phase of PACNS. Some experts suggest avoiding intravenous pulse glucocorticoids, since this regimen is more likely to cloud the clinical picture by contributing to steroid-induced mental status changes, and suggest beginning the patient on the equivalent of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 1 mg/kg per day (to a maximum of 80 mg/day, or its equivalent) until the diagnostic evaluation is complete.</p><p class="headingAnchor" id="H32"><span class="h2">Treatment of PACNS</span><span class="headingEndMark"> — </span>Biopsy-confirmed cases with a picture of granulomatous inflammation on pathology, typical of granulomatous angiitis of the CNS (GACNS), should be treated with a combination of glucocorticoids and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> [<a href="#rid19">19,21,22</a>]. Failure to respond to these drugs after an appropriate treatment regimen should prompt the evaluation for an alternative diagnosis before additional treatment with an alternative immunosuppressive drug. <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> may be used in patients who are intolerant of cyclophosphamide (see <a class="local">'Rituximab'</a> below). The glucocorticoid and cyclophosphamide regimens used for PACNS are discussed below. (See <a class="local">'Glucocorticoids'</a> below and <a class="local">'Cyclophosphamide'</a> below.)</p><p>The treatment of atypical/possible PACNS should be tailored according to the severity and the extent of the neurologic involvement. Atypical/possible PACNS patients should be treated initially with a high dose of glucocorticoids [<a href="#rid22">22</a>], and then tapered slowly. The decision of adding <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> to the treatment regimen should be individualized according to the extent and the gravity of the neurologic deficits.</p><p class="headingAnchor" id="H33"><span class="h3">Glucocorticoids</span><span class="headingEndMark"> — </span>High-dose glucocorticoids are required to achieve disease control in PACNS. We initiate therapy with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at a dose of 1 mg/kg per day to a maximum of 80 mg/day, or its equivalent. Some experts begin with intravenous <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">methylprednisolone</a>, 15 mg/kg each day for three days [<a href="#rid59">59</a>]. Daily prednisone is begun on day 4. </p><p>Glucocorticoids are associated with many potential treatment-related morbidities (see  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>). Prophylactic approaches to prevent bone loss and opportunistic infections are discussed below. (See <a class="local">'Prophylactic therapies'</a> below.)</p><p class="headingAnchor" id="H34"><span class="h3">Cyclophosphamide</span><span class="headingEndMark"> — </span>Either daily oral or intermittent (usually monthly) intravenous <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> is reasonable as part of a remission induction strategy in PACNS [<a href="#rid60">60</a>]. Some clinicians prefer oral cyclophosphamide because of the ability to titrate the dose on a daily basis if necessary, thereby decreasing the likelihood of severe leukopenia. Other clinicians are more familiar with the intermittent administration of cyclophosphamide.</p><p>Oral <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> is begun at a dose of 1.5 to 2 mg/kg per day. In this setting, the white blood cell count (WBC) must be closely monitored and the cyclophosphamide dose adjusted to avoid severe leukopenia. The WBC count should remain above 3500/microL. The duration of the cyclophosphamide therapy is generally between three and six months, depending on when remission occurs and if there are any potential side effects that preclude the use of cyclophosphamide. (See  <a class="medical medical_review" href="/z/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases", section on 'Monitoring of oral CYC dosing'</a>.)</p><p>The typical regimen for intravenous <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> is 600 to 750 mg/m<sup>2</sup>, infused once a month, generally for between three and six months [<a href="#rid59">59</a>]. A reduction in cyclophosphamide dose is necessary if there is significant renal insufficiency with not more than 500 mg/m<sup>2</sup> for patients with an estimated glomerular filtration rate less than 20 mL/min.</p><p class="headingAnchor" id="H517928519"><span class="h3">Rituximab</span><span class="headingEndMark"> — </span>Limited data are available for the use of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> in PACNS [<a href="#rid61">61,62</a>]. Three cases were reported that described clinical and radiographic improvement in adults with PACNS after treatment with rituximab (either as two 1 gram infusions separated by 14 days or as 375 mg/m<sup>2</sup> weekly for four weeks) [<a href="#rid61">61,62</a>]. In one case, the diagnosis was made by angiographic findings and an abnormal cerebrospinal fluid (CSF), and rituximab was given as first-line therapy [<a href="#rid61">61</a>]. In another case, the diagnosis of PACNS was pathologically validated with evidence of a lymphocytic vasculitic process in the brain and spinal cord, and rituximab was used after the patient failed to improve with five monthly <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> infusions [<a href="#rid61">61</a>]. In the third case, the diagnosis was confirmed by pathologic findings of granulomatous vasculitis, and rituximab was given as first-line therapy [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H35"><span class="h2">Prophylactic therapies</span><span class="headingEndMark"> — </span>The toxicities of PACNS treatments require the use of several prophylactic therapies to prevent bone loss and opportunistic infections.</p><p class="headingAnchor" id="H36"><span class="h3">Osteoporosis prevention</span><span class="headingEndMark"> — </span>All patients treated with high-dose glucocorticoids are at risk for glucocorticoid-induced osteoporosis. The prevention and treatment of glucocorticoid-induced osteoporosis are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">"Prevention and treatment of glucocorticoid-induced osteoporosis"</a>.)</p><p class="headingAnchor" id="H37"><span class="h3">Opportunistic infections</span><span class="headingEndMark"> — </span>Glucocorticoid and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> therapy are associated with an increased risk for opportunistic infection. <em>Pneumocystis jirovecii</em>, a common pathogen in immunosuppressed hosts, may cause a life-threatening pneumonia.</p><p>In patients treated with the combination of high-dose <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> and another immunosuppressive agent, we recommend prophylaxis against <em>Pneumocystis </em>pneumonia (PCP). Options for prophylactic regimens are discussed separately. The optimal duration of <em>Pneumocystis</em> prophylaxis after immunosuppressive therapy is tapered has not been defined. (See  <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">"Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'</a>.)</p><p class="headingAnchor" id="H38"><span class="h3">Other</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">Cyclophosphamide</a> is associated with many potential treatment-related morbidities. Prophylactic approaches to these complications are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases"</a>.)</p><p class="headingAnchor" id="H39"><span class="h2">Monitoring treatment</span><span class="headingEndMark"> — </span>The response to treatment is monitored by periodic reassessment of symptoms, neurologic findings, and neuroimaging abnormalities. It is very important to differentiate between disease damage and disease progression. Neurologic deficits due to cerebral or cerebellar infarction may resolve slowly or not at all. Thus, for some patients, a response to treatment may only be indicated by symptomatic improvement (eg, resolution of headache), but not the resolution of magnetic resonance (MR) lesions. A lack of new lesions on MRI is a more reliable way to assess for progression of the disease.</p><p>With respect to neuroimaging, noninvasive studies are preferred to repeated angiography. A follow-up MR should be obtained four to six weeks after beginning treatment, then every three to six months throughout therapy, and subsequently according to the evolution of the disease.</p><p>During the use of immunosuppressive treatment, patients require close clinical follow-up and laboratory monitoring in order to avoid preventable adverse effects of therapy. As an example, patients on daily <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> should have complete blood counts checked every two weeks. (See  <a class="medical medical_review" href="/z/d/html/7963.html" rel="external">"General principles of the use of cyclophosphamide in rheumatic diseases", section on 'Monitoring of oral CYC dosing'</a>.)</p><p class="headingAnchor" id="H40"><span class="h2">Duration of therapy and management of recurrent disease</span><span class="headingEndMark"> — </span>There are limited data available that address the optimal duration of therapy or the treatment of disease recurrence. The following approaches are based on the authors' experience and extrapolation from the treatment of other forms of vasculitis.</p><p class="headingAnchor" id="H41"><span class="h3">Glucocorticoid taper</span><span class="headingEndMark"> — </span>After four to six weeks at the initial dose, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> tapering should begin. There is no standard tapering regimen for PACNS, but regimens similar to the one outlined below are appropriate. Assuming that a patient begins prednisone treatment at 60 mg/day and remains on this dose for six weeks, the following taper will require a total of 26 weeks to reach a daily dose of 5 mg:</p><p class="bulletIndent1"><span class="glyph">●</span>The <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> dose should be tapered by 10 mg each week until a dose of 40 mg/day is reached.</p><p class="bulletIndent1"><span class="glyph">●</span>After one week on 40 mg per day, the <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> dose should be tapered by 5 mg each week until the patient reaches 20 mg/day.</p><p class="bulletIndent1"><span class="glyph">●</span>After one week on 20 mg/day, the <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> dose should be tapered by 2.5 mg each week until the patient reaches 10 mg/day.</p><p class="bulletIndent1"><span class="glyph">●</span>After one week on 10 mg/day, the <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> dose should be tapered by 1 mg every two weeks until the patient reaches 5 mg/day.</p><p class="bulletIndent1"><span class="glyph">●</span>After two weeks on 5 mg/day, the daily <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> dose should be tapered by 1 mg each month until the taper has been completed.</p><p></p><p>Deviations from this regimen may be necessary if patients develop a significant complication of glucocorticoid therapy or experience disease recurrence. If a flare in symptoms occurs while the glucocorticoid dose is being lowered, the dose should be increased to the lowest amount that previously suppressed the clinical manifestations. Once the patient improves to the level of their prior status or stabilizes, reductions in the dose can be tried again.</p><p class="headingAnchor" id="H42"><span class="h3">Discontinuing cyclophosphamide</span><span class="headingEndMark"> — </span>Three to six months of <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> is sufficient for many patients. At this time, cyclophosphamide should be discontinued after approximately six months and replaced with a less toxic medication for an additional six to twelve months of maintenance therapy, in a manner that is similar to that of the management of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis.</p><p>Some clinicians switch from <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> to <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a> (2 mg/kg) or <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, which are favored over <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, given its limited ability to cross the blood brain barrier. Data on the duration of the maintenance therapy is not available, and the decision on the duration of the therapy should be individualized, based upon the response to therapy. (See  <a class="medical medical_review" href="/z/d/html/3105.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Induction and maintenance therapy", section on 'Maintenance therapy'</a>.)</p><p>In a single-center cohort of 44 patients with PACNS, relapses were reported in up to 59 percent of patients; relapse was defined as a reoccurrence or worsening of neurologic symptoms or worsening of existing and/or evidence of new abnormal neuroimaging findings on MRI consistent with PACNS activity [<a href="#rid63">63</a>]. Male patients were found to have a higher rate of relapse, but other predictors for relapses that had been identified from other case series were not confirmed in this study. Thus, more studies using a more uniform treatment regimen and relapse definition are needed to help identify factors affecting risk of relapse and response to therapy.</p><p class="headingAnchor" id="H541175516"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110743.html" rel="external">"Society guideline links: Vasculitis"</a>.)</p><p class="headingAnchor" id="H43"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Primary angiitis of the central nervous system (PACNS) most commonly involves small- and medium-sized cerebral blood vessels resulting in symptoms and signs of CNS dysfunction. It is defined by inflammation of the cerebral vasculature without angiitis in other organs. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PACNS is a rare disease, and the cause is unknown. The median age at diagnosis is 50 years, although it can occur at almost every age. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Etiopathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PACNS is characterized by a long prodromal period, with few patients presenting acutely. The vasculitis can affect any part of the CNS, causing the clinical manifestations to be highly variable and nonspecific. The most commonly reported symptom is a subacute and insidious headache. Other symptoms include cognitive impairment, stroke, and transient ischemic attack. Patients with PACNS who develop strokes usually present with more than a single stroke in different anatomic areas. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of PACNS is challenging as the symptoms are generally nonspecific and there is no specific diagnostic test. The workup for patients who may have PACNS must proceed simultaneously with the systematic evaluation and exclusion of other disorders. While there is no characteristic presentation, there are some scenarios that are highly suspicious. PACNS should be suspected when strokes, more often recurrent, occur in young patients with no identifiable cardiovascular or hypercoagulable risk factors; or in the setting of chronic meningitis, recurrent focal neurologic symptoms, unexplained diffuse neurologic dysfunction, abnormal cerebrovascular imaging obtained in the setting of an unexplained neurological deficit, or unexplained spinal cord dysfunction not associated with systemic disease or any other process. (See <a class="local">'Diagnostic approach'</a> above and <a class="local">'When to suspect the diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients in whom a diagnosis of PACNS is suspected, an alternative diagnosis is more likely to be correct. As a result, careful exclusion of other disorders is essential. The most common clinical and radiologic mimickers are the reversible cerebral vasoconstriction syndromes (RCVS). Other alternative diagnoses include infection, systemic vasculitides and other systemic rheumatic diseases, atherosclerosis, cerebral emboli, intravascular lymphoma, and moyamoya. (See <a class="local">'Alternative diagnoses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laboratory testing and serological assays are used primarily to exclude other etiologies of CNS dysfunction. Analysis of the cerebrospinal fluid (CSF) is a crucial part of the evaluation of patients with potential PACNS and should be performed in all patents unless there are contraindications. The CSF is abnormal in 80 to 90 percent of patients with pathologically documented disease. CSF findings are nonspecific but most commonly include an elevated CSF protein and a modest lymphocytic pleocytosis. (See <a class="local">'Evaluation'</a> above and <a class="local">'Laboratory testing to exclude alternative diagnoses'</a> above and <a class="local">'Lumbar puncture'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Various neuroimaging modalities can be used to assess for both parenchymal and vascular abnormalities in the evaluation of suspected PACNS. MRI should be performed in all patients. The selection of additional neuroimaging modalities depends on the initial MRI findings and individual patient characteristics. Conventional angiography remains an important part of the diagnostic testing for suspected PACNS, and our authors obtain angiography in patients who have MRI findings of multiple cortical and subcortical infarcts that are otherwise unexplained. Angiography can detect segmental narrowing in multiple vessels that are typical of, though not pathognomonic for, PACNS, and help further rule out alternative diagnoses such as atherosclerosis, moyamoya, and dissection. These tests may also be helpful in selecting a location for brain biopsy if needed. (See <a class="local">'Neuroimaging'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A brain biopsy should be performed in most patients with suspected PACNS. A biopsy will help histologically identify PACNS as well as exclude other lesions or vasculitis mimics, particularly infection or malignancy. (See <a class="local">'Brain and leptomeningeal biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of PACNS is based upon a constellation of symptoms and signs in the setting of supportive studies, and the exclusion of alternative diagnoses. The diagnosis can usually be made when all of the following are present (see <a class="local">'Establishing the diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An acquired otherwise unexplained neurological deficit</p><p class="bulletIndent2"><span class="glyph">•</span>Evidence of either classic angiographic or histopathologic features of angiitis within the CNS</p><p class="bulletIndent2"><span class="glyph">•</span>No evidence of systemic vasculitis or any other condition that could elicit the angiographic or pathologic findings</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are patients in whom the diagnosis of PACNS is made without all the meeting the criteria described above. In such scenarios, the term "atypical/possible PACNS" has been used to describe the uncertainty about the diagnosis or the variation from the typical pathologic findings. This usually includes lymphocytic PACNS, angiographically defined PACNS, and a mass lesion presentation. (See <a class="local">'Establishing the diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest treating PACNS with a combination of glucocorticoids and <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Treatment of atypical PACNS should be individualized according to the severity and the extent of the neurologic deficit. (See <a class="local">'Treatment of PACNS'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We use measures to prevent osteoporosis and <em>Pneumocystis</em> infections during the treatment of PACNS. (See <a class="local">'Prophylactic therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The response to treatment is monitored by periodic reassessment of symptoms, neurologic findings, and neuroimaging abnormalities. It is important to differentiate between disease damage and disease progression. Neurologic deficits due to cerebral or cerebellar infarction may resolve slowly or not at all. Thus, for some patients, a response to treatment may only be indicated by symptomatic improvement (eg, resolution of headache), but not the resolution of magnetic resonance (MR) lesions. A lack of new lesions on MRI is a more reliable way to assess for progression of the disease. A follow-up MR should be obtained four to six weeks after beginning treatment, then every three to six months throughout therapy, and subsequently according to the evolution of the disease. (See <a class="local">'Monitoring treatment'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Salvarani C, Brown RD Jr, Calamia KT, et al. Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol 2007; 62:442.</a></li><li><a class="nounderline abstract_t">Calabrese LH, Duna GF, Lie JT. Vasculitis in the central nervous system. Arthritis Rheum 1997; 40:1189.</a></li><li><a class="nounderline abstract_t">Sigal LH. The neurologic presentation of vasculitic and rheumatologic syndromes. A review. Medicine (Baltimore) 1987; 66:157.</a></li><li><a class="nounderline abstract_t">Thomas L, Davidson M, McCluskey RT. Studies of PPLO infection. I. The production of cerebral polyarteritis by Mycoplasma gallisepticum in turkeys; the neurotoxic property of the Mycoplasma. J Exp Med 1966; 123:897.</a></li><li><a class="nounderline abstract_t">Alexander JJ, Lasky AS, Graf WD. Stroke associated with central nervous system vasculitis after West Nile virus infection. J Child Neurol 2006; 21:623.</a></li><li><a class="nounderline abstract_t">Outteryck O, Sénéchal O, Berteloot D, et al. [Cerebral vasculitis secondary to Varicella-Zoster virus infection]. Rev Neurol (Paris) 2005; 161:836.</a></li><li><a class="nounderline abstract_t">Bhat G, Mathur DS, Saxena GN, et al. Granulomatous angiitis of the central nervous system associated with herpes zoster. J Assoc Physicians India 2002; 50:977.</a></li><li><a class="nounderline abstract_t">Brannagan TH 3rd. Retroviral-associated vasculitis of the nervous system. Neurol Clin 1997; 15:927.</a></li><li><a class="nounderline abstract_t">Nogueras C, Sala M, Sasal M, et al. Recurrent stroke as a manifestation of primary angiitis of the central nervous system in a patient infected with human immunodeficiency virus. Arch Neurol 2002; 59:468.</a></li><li><a class="nounderline abstract_t">Kossorotoff M, Touzé E, Godon-Hardy S, et al. Cerebral vasculopathy with aneurysm formation in HIV-infected young adults. Neurology 2006; 66:1121.</a></li><li><a class="nounderline abstract_t">van der Ven AJ, van Oostenbrugge RJ, Kubat B, Tervaert JW. Cerebral vasculitis after initiation antiretroviral therapy. AIDS 2002; 16:2362.</a></li><li><a class="nounderline abstract_t">Scolding NJ, Joseph F, Kirby PA, et al. Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain 2005; 128:500.</a></li><li><a class="nounderline abstract_t">Hashizume Y, Yoshida M, Suzuki E, Hirayama M. A 65-year-old man with headaches and left homonymous hemianopsia. Neuropathology 2004; 24:350.</a></li><li><a class="nounderline abstract_t">Harkness KA, Coles A, Pohl U, et al. Rapidly reversible dementia in cerebral amyloid inflammatory vasculopathy. Eur J Neurol 2004; 11:59.</a></li><li><a class="nounderline abstract_t">Tamargo RJ, Connolly ES Jr, McKhann GM, et al. Clinicopathological review: primary angiitis of the central nervous system in association with cerebral amyloid angiopathy. Neurosurgery 2003; 53:136.</a></li><li><a class="nounderline abstract_t">Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-2000. A 63-year-old man with changes in behavior and ataxia. N Engl J Med 2000; 342:957.</a></li><li><a class="nounderline abstract_t">Salvarani C, Brown RD Jr, Calamia KT, et al. Primary central nervous system vasculitis: comparison of patients with and without cerebral amyloid angiopathy. Rheumatology (Oxford) 2008; 47:1671.</a></li><li><a class="nounderline abstract_t">Fountain NB, Eberhard DA. Primary angiitis of the central nervous system associated with cerebral amyloid angiopathy: report of two cases and review of the literature. Neurology 1996; 46:190.</a></li><li><a class="nounderline abstract_t">Hajj-Ali RA, Calabrese LH. Primary angiitis of the central nervous system. Autoimmun Rev 2013; 12:463.</a></li><li><a class="nounderline abstract_t">Hajj-Ali RA, Calabrese LH. Diagnosis and classification of central nervous system vasculitis. J Autoimmun 2014; 48-49:149.</a></li><li><a class="nounderline abstract_t">de Boysson H, Zuber M, Naggara O, et al. Primary angiitis of the central nervous system: description of the first fifty-two adults enrolled in the French cohort of patients with primary vasculitis of the central nervous system. Arthritis Rheumatol 2014; 66:1315.</a></li><li><a class="nounderline abstract_t">Salvarani C, Brown RD Jr, Christianson TJ, et al. Adult primary central nervous system vasculitis treatment and course: analysis of one hundred sixty-three patients. Arthritis Rheumatol 2015; 67:1637.</a></li><li><a class="nounderline abstract_t">Giannini C, Salvarani C, Hunder G, Brown RD. Primary central nervous system vasculitis: pathology and mechanisms. Acta Neuropathol 2012; 123:759.</a></li><li><a class="nounderline abstract_t">Salvarani C, Brown RD Jr, Calamia KT, et al. Primary CNS vasculitis with spinal cord involvement. Neurology 2008; 70:2394.</a></li><li><a class="nounderline abstract_t">Wilson MR, O'Donovan BD, Gelfand JM, et al. Chronic Meningitis Investigated via Metagenomic Next-Generation Sequencing. JAMA Neurol 2018; 75:947.</a></li><li><a class="nounderline abstract_t">Nagel MA, Bubak AN. Varicella Zoster Virus Vasculopathy. J Infect Dis 2018; 218:S107.</a></li><li><a class="nounderline abstract_t">Nagel MA, Gilden D. Neurological complications of varicella zoster virus reactivation. Curr Opin Neurol 2014; 27:356.</a></li><li><a class="nounderline abstract_t">Barinagarrementeria F, Cantú C. Frequency of cerebral arteritis in subarachnoid cysticercosis: an angiographic study. Stroke 1998; 29:123.</a></li><li><a class="nounderline abstract_t">Calabrese LH, Dodick DW, Schwedt TJ, Singhal AB. Narrative review: reversible cerebral vasoconstriction syndromes. Ann Intern Med 2007; 146:34.</a></li><li><a class="nounderline abstract_t">Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium. Arthritis Rheum 1996; 39:9.</a></li><li><a class="nounderline abstract_t">Ellis SG, Verity MA. Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955--1977. Semin Arthritis Rheum 1979; 8:212.</a></li><li><a class="nounderline abstract_t">Hanly JG, Walsh NM, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol 1992; 19:732.</a></li><li><a class="nounderline abstract_t">Lyons MK, Caselli RJ, Parisi JE. Nonvasculitic autoimmune inflammatory meningoencephalitis as a cause of potentially reversible dementia: report of 4 cases. J Neurosurg 2008; 108:1024.</a></li><li><a class="nounderline abstract_t">Calabrese LH, Mallek JA. Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine (Baltimore) 1988; 67:20.</a></li><li><a class="nounderline abstract_t">Horowitz DR, Tuhrim S, Budd J, Goldman ME. Aortic plaque in patients with brain ischemia: diagnosis by transesophageal echocardiography. Neurology 1992; 42:1602.</a></li><li><a class="nounderline abstract_t">Lie JT. Malignant angioendotheliomatosis (intravascular lymphomatosis) clinically simulating primary angiitis of the central nervous system. Arthritis Rheum 1992; 35:831.</a></li><li><a class="nounderline abstract_t">Demirer T, Dail DH, Aboulafia DM. Four varied cases of intravascular lymphomatosis and a literature review. Cancer 1994; 73:1738.</a></li><li><a class="nounderline abstract_t">Nakahara T, Saito T, Muroi A, et al. Intravascular lymphomatosis presenting as an ascending cauda equina: conus medullaris syndrome: remission after biweekly CHOP therapy. J Neurol Neurosurg Psychiatry 1999; 67:403.</a></li><li><a class="nounderline abstract_t">Susac JO, Hardman JM, Selhorst JB. Microangiopathy of the brain and retina. Neurology 1979; 29:313.</a></li><li><a class="nounderline abstract_t">Kleffner I, Deppe M, Mohammadi S, et al. Diffusion tensor imaging demonstrates fiber impairment in Susac syndrome. Neurology 2008; 70:1867.</a></li><li><a class="nounderline abstract_t">Do TH, Fisch C, Evoy F. Susac syndrome: report of four cases and review of the literature. AJNR Am J Neuroradiol 2004; 25:382.</a></li><li><a class="nounderline abstract_t">Susac JO, Murtagh FR, Egan RA, et al. MRI findings in Susac's syndrome. Neurology 2003; 61:1783.</a></li><li><a class="nounderline abstract_t">Dimauro S, Hirano M. Pedaling from genotype to phenotype. Arch Neurol 2006; 63:1679.</a></li><li><a class="nounderline abstract_t">Richards A, van den Maagdenberg AM, Jen JC, et al. C-terminal truncations in human 3'-5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet 2007; 39:1068.</a></li><li><a class="nounderline abstract_t">Singhal AB, Hajj-Ali RA, Topcuoglu MA, et al. Reversible cerebral vasoconstriction syndromes: analysis of 139 cases. Arch Neurol 2011; 68:1005.</a></li><li><a class="nounderline abstract_t">Alhalabi M, Moore PM. Serial angiography in isolated angiitis of the central nervous system. Neurology 1994; 44:1221.</a></li><li><a class="nounderline abstract_t">Pomper MG, Miller TJ, Stone JH, et al. CNS vasculitis in autoimmune disease: MR imaging findings and correlation with angiography. AJNR Am J Neuroradiol 1999; 20:75.</a></li><li><a class="nounderline abstract_t">Molloy ES, Singhal AB, Calabrese LH. Tumour-like mass lesion: an under-recognised presentation of primary angiitis of the central nervous system. Ann Rheum Dis 2008; 67:1732.</a></li><li><a class="nounderline abstract_t">Kadkhodayan Y, Alreshaid A, Moran CJ, et al. Primary angiitis of the central nervous system at conventional angiography. Radiology 2004; 233:878.</a></li><li><a class="nounderline abstract_t">Calabrese LH, Furlan AJ, Gragg LA, Ropos TJ. Primary angiitis of the central nervous system: diagnostic criteria and clinical approach. Cleve Clin J Med 1992; 59:293.</a></li><li><a class="nounderline abstract_t">Vollmer TL, Guarnaccia J, Harrington W, et al. Idiopathic granulomatous angiitis of the central nervous system. Diagnostic challenges. Arch Neurol 1993; 50:925.</a></li><li><a class="nounderline abstract_t">Bai HX, Zou Y, Lee AM, et al. Diagnostic Value and Safety of Brain Biopsy in Patients With Cryptogenic Neurological Disease: A Systematic Review and Meta-analysis of 831 Cases. Neurosurgery 2015; 77:283.</a></li><li><a class="nounderline abstract_t">Alrawi A, Trobe JD, Blaivas M, Musch DC. Brain biopsy in primary angiitis of the central nervous system. Neurology 1999; 53:858.</a></li><li><a class="nounderline abstract_t">Chu CT, Gray L, Goldstein LB, Hulette CM. Diagnosis of intracranial vasculitis: a multi-disciplinary approach. J Neuropathol Exp Neurol 1998; 57:30.</a></li><li><a class="nounderline abstract_t">Krawczyk M, Barra LJ, Sposato LA, Mandzia JL. Primary CNS vasculitis: A systematic review on clinical characteristics associated with abnormal biopsy and angiography. Autoimmun Rev 2021; 20:102714.</a></li><li><a class="nounderline abstract_t">Parisi JE, Moore PM. The role of biopsy in vasculitis of the central nervous system. Semin Neurol 1994; 14:341.</a></li><li><a class="nounderline abstract_t">Miller DV, Salvarani C, Hunder GG, et al. Biopsy findings in primary angiitis of the central nervous system. Am J Surg Pathol 2009; 33:35.</a></li><li><a class="nounderline abstract_t">Lie JT. Classification and histopathologic spectrum of central nervous system vasculitis. Neurol Clin 1997; 15:805.</a></li><li><a class="nounderline abstract_t">Guillevin L, Pagnoux C. When should immunosuppressants be prescribed to treat systemic vasculitides? Intern Med 2003; 42:313.</a></li><li><a class="nounderline abstract_t">Gayraud M, Guillevin L, Cohen P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 1997; 36:1290.</a></li><li><a class="nounderline abstract_t">De Boysson H, Arquizan C, Guillevin L, Pagnoux C. Rituximab for primary angiitis of the central nervous system: report of 2 patients from the French COVAC cohort and review of the literature. J Rheumatol 2013; 40:2102.</a></li><li><a class="nounderline abstract_t">Salvarani C, Brown RD Jr, Huston J 3rd, et al. Treatment of primary CNS vasculitis with rituximab: case report. Neurology 2014; 82:1287.</a></li><li><a class="nounderline abstract_t">Schuster S, Ozga AK, Stellmann JP, et al. Relapse rates and long-term outcome in primary angiitis of the central nervous system. J Neurol 2019; 266:1481.</a></li></ol></div><div id="topicVersionRevision">Topic 8230 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17924545" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Primary central nervous system vasculitis: analysis of 101 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9214418" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Vasculitis in the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3553845" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The neurologic presentation of vasculitic and rheumatologic syndromes. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5938817" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Studies of PPLO infection. I. The production of cerebral polyarteritis by Mycoplasma gallisepticum in turkeys; the neurotoxic property of the Mycoplasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16970859" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Stroke associated with central nervous system vasculitis after West Nile virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16244567" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : [Cerebral vasculitis secondary to Varicella-Zoster virus infection].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12126361" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Granulomatous angiitis of the central nervous system associated with herpes zoster.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9367973" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Retroviral-associated vasculitis of the nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11890855" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Recurrent stroke as a manifestation of primary angiitis of the central nervous system in a patient infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16606935" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cerebral vasculopathy with aneurysm formation in HIV-infected young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12441820" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cerebral vasculitis after initiation antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15659428" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15641598" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : A 65-year-old man with headaches and left homonymous hemianopsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14692890" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Rapidly reversible dementia in cerebral amyloid inflammatory vasculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12823882" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinicopathological review: primary angiitis of the central nervous system in association with cerebral amyloid angiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10738055" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-2000. A 63-year-old man with changes in behavior and ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18753193" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Primary central nervous system vasculitis: comparison of patients with and without cerebral amyloid angiopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8559373" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Primary angiitis of the central nervous system associated with cerebral amyloid angiopathy: report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22971519" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Primary angiitis of the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24491822" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Diagnosis and classification of central nervous system vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24782189" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Primary angiitis of the central nervous system: description of the first fifty-two adults enrolled in the French cohort of patients with primary vasculitis of the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25708615" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Adult primary central nervous system vasculitis treatment and course: analysis of one hundred sixty-three patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22421812" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Primary central nervous system vasculitis: pathology and mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18541872" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Primary CNS vasculitis with spinal cord involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29710329" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Chronic Meningitis Investigated via Metagenomic Next-Generation Sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30247600" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Varicella Zoster Virus Vasculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24792344" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Neurological complications of varicella zoster virus reactivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9445339" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Frequency of cerebral arteritis in subarachnoid cysticercosis: an angiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17200220" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Narrative review: reversible cerebral vasoconstriction syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8546744" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Interactions of inflammatory cells and activated endothelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/424765" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Central nervous system involvement in systemic lupus erythematosus: a review of neuropathologic findings in 57 cases, 1955--1977.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1613703" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Brain pathology in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18447724" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Nonvasculitic autoimmune inflammatory meningoencephalitis as a cause of potentially reversible dementia: report of 4 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3275856" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1641158" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Aortic plaque in patients with brain ischemia: diagnosis by transesophageal echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1301018" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Malignant angioendotheliomatosis (intravascular lymphomatosis) clinically simulating primary angiitis of the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8156502" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Four varied cases of intravascular lymphomatosis and a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10449569" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Intravascular lymphomatosis presenting as an ascending cauda equina: conus medullaris syndrome: remission after biweekly CHOP therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/571975" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Microangiopathy of the brain and retina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17959768" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Diffusion tensor imaging demonstrates fiber impairment in Susac syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15037459" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Susac syndrome: report of four cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14694047" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : MRI findings in Susac's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17172605" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Pedaling from genotype to phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17660820" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : C-terminal truncations in human 3'-5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21482916" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Reversible cerebral vasoconstriction syndromes: analysis of 139 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8035919" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Serial angiography in isolated angiitis of the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9974060" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : CNS vasculitis in autoimmune disease: MR imaging findings and correlation with angiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18625623" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Tumour-like mass lesion: an under-recognised presentation of primary angiitis of the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15498898" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Primary angiitis of the central nervous system at conventional angiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1516217" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Primary angiitis of the central nervous system: diagnostic criteria and clinical approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8363446" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Idiopathic granulomatous angiitis of the central nervous system. Diagnostic challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25856111" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Diagnostic Value and Safety of Brain Biopsy in Patients With Cryptogenic Neurological Disease: A Systematic Review and Meta-analysis of 831 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10489055" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Brain biopsy in primary angiitis of the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9600195" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Diagnosis of intracranial vasculitis: a multi-disciplinary approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33197577" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Primary CNS vasculitis: A systematic review on clinical characteristics associated with abnormal biopsy and angiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7709084" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The role of biopsy in vasculitis of the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18941399" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Biopsy findings in primary angiitis of the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9367965" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Classification and histopathologic spectrum of central nervous system vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12729318" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : When should immunosuppressants be prescribed to treat systemic vasculitides?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9448590" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24293623" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Rituximab for primary angiitis of the central nervous system: report of 2 patients from the French COVAC cohort and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24598711" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Treatment of primary CNS vasculitis with rituximab: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30904954" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Relapse rates and long-term outcome in primary angiitis of the central nervous system.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
